Items Tagged with 'Pfizer'

ARTICLES

PFE Complete $11.85 billion Sale

Pfizer Completes Sale of Nutrition Business to Nestlé

On November 30, Pfizer Inc. (NYSE: PFE) announced that it has completed the sale of its Nutrition business to Nestlé for $11.85 billion in cash, following the conclusion of the required regulatory process in most markets.


Read More
PFE Announces Revenues of $14.0 billion

Pfizer Reports Third-Quarter 2012 Results

On November 1, 2012, Pfizer Inc. (NYSE: PFE) reported financial results for third-quarter 2012. Third-quarter 2012 revenues were $14.0 billion, a decrease of 16% compared with $16.6 billion in the year-ago quarter, which reflects an operational decline of $1.9 billion, or 12%, and the unfavorable impact of foreign exchange of $699 million, or 4%.


Read More
PFE Obtains FDA Approval for Lyrica

Pfizer FDA Approval Received

On June 21, 2012, Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved the use of Lyrica® (pregabalin) capsules CV for the management of neuropathic pain associated with spinal cord injury.


Read More
Pfizer Buys Vitamin C Icon

Pfizer Acquisition Announced

On February 27, 2012, Pfizer Inc. (NYSE:PFE) announced the acquisition of privately-held Alacer Corp....


Read More

Pfizer Recall Announced

On February 1, 2012, Pfizer Inc. (NYSE: PFE) announced that it has voluntarily recalled 14 lots of Lo/Ovral®-28 (norgestrel and ethinyl estradiol)Tablets and 14 lots of Norgestrel and Ethinyl Estradiol Tablets (generic) for customers in the U.S. market.


Read More

Pfizer FDA Approval Received

On January 27, 2012, Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved INLYTA® (axitinib), a kinase inhibitor, for the treatment of patients with advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.


Read More

Turnaround Investment Strategies

stock market advice

stock market advice

Distressed Investing Blog

Distressed Investing Blog

Cash in on Interest Rate Hike with Bank Stock Picks

Investors have found many things to dislike about banks, such as increasing regulation and low lending margins in these days of miniscule interest rates. I think the banks may be about to fare better, making them one of the few sectors that look cheap in the current market. Read More.

Your Financial Security is Serious Business...

so why should you trust The Turnaround Letter?

  • Ranked as #1 Performing Newsletter for 15-Yr. Returns: Turnaround Letter's 12.7% vs. S&P's 2.7%
  • 28+ Years of Turnaround Investing Experience & Reliable Stock Market Advice
  • Diverse Monthly Stock Picks Personally Selected by George Putnam

Dividend Turnaround Stock Picks

In this MoneyShow.com "Daily Guru" feature interview,George details three key advantages of dividend-paying turnaround stocks—and names four timely value investing stock picks suitable for conservative investors looking to cash in!

 

Dividend Turnaround Stocks